Anteris’ DurAVR THV Demonstrates 1% Heart Failure Hospitalization, Single-Digit Gradients and No Valve-Related Deaths at 1 Year in Patients with Small Aortic Annuli
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Anteris Technologies Global (AVR) reported one-year DurAVR heart valve results in patients with severe aortic valve narrowing and small valve openings. Among 100 patients pooled from EMBARK and early feasibility studies, 1% were hospitalized for heart failure and no valve-related deaths were reported through one year. Mean pressure across the valve fell from 48.1 to 8.9 mmHg, with no moderate or severe leakage around the valve. The share of patients with no or mild symptoms rose from 39% to 96%.
At one year, all-cause mortality was 6%, stroke occurred in 3% and 9% received a new permanent pacemaker. At 30 days, 97% were free from moderate or severe mismatch between the valve opening and body size. The pivotal PARADIGM trial is enrolling in the United States and Europe to compare DurAVR with commercially available transcatheter valves.
Positive
- Minor pointHeart failure hospitalization was 1% at one year in the 100-patient DurAVR cohort
- Minor pointValve-related deaths were not reported through one year
- Minor pointMean pressure gradient fell from 48.1 ± 17.0 mmHg at baseline to 8.9 ± 4.3 mmHg at one year
- Minor pointMean effective valve opening area rose from 0.8 ± 0.2 cm² at baseline to 2.2 ± 0.9 cm² at one year
- Minor pointModerate or severe leakage around the valve was not observed through one year
6 minor points
- Minor pointModerate or severe deterioration in valve function was not observed at one year
- Minor pointPatients with no or mild symptoms increased from 39% at baseline to 96% at one year
- Minor pointSymptom improvement was reported in 81% of patients at one year
- Minor pointValve fit was free from moderate or severe mismatch in 97% of patients at 30 days
- Minor pointLeft ventricular mass fell 24% at one year in a 64-patient cardiac MRI substudy
- Minor point. Forward-looking: it has not happened yet and may not happen.Pivotal PARADIGM trial is enrolling in the United States and Europe, with approximately 1,000 patients planned for its randomized cohort
Negative
- Minor pointAll-cause mortality was 6% at one year
- Minor pointStroke occurred in 3% of patients at one year
- Minor pointNew permanent pacemaker implantation occurred in 9% of patients at one year
News Explained
Commercial use remains unavailable; the roughly one-thousand-patient randomized trial will test a one-year clinical composite.
At the
The next evidence checkpoint is the actively enrolling PARADIGM trial, a randomized comparison planned for about 1,000 patients assigned 1:1 to DurAVR or approved commercial valves.
The trial will test non-inferiority on a one-year composite of all-cause mortality, all stroke, and cardiovascular hospitalization.
Key Figures
- Patients
- 100 patients
- Pooled cohort with severe aortic stenosis and small aortic annuli
- Heart failure hospitalization
- 1%
- At 1 year
- Mean pressure gradient
- 48.1 ± 17.0 to 8.9 ± 4.3 mmHg
- Baseline to 1 year
- Mean effective orifice area
- 0.8 ± 0.2 to 2.2 ± 0.9 cm2
- Baseline to 1 year
- Freedom from moderate or severe PPM
- 97%
- At 30 days
- NYHA class I/II
- 39% to 96%
- Baseline to 1 year
- All-cause mortality
- 6%
- At 1 year
- Left ventricular mass regression
- 24%
- At 1 year in a cardiac magnetic resonance substudy (n = 64)
Key Terms
paravalvular leak medical
prosthesis-patient mismatch medical
effective orifice area medical
nyha medical
sts-prom medical
tavr medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Late-breaking 1-year data in 100 patients presented at PCR London Valves 2026: No moderate or severe paravalvular leak,
MINNEAPOLIS and BRISBANE, Nov. 22, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) today announced 1-year clinical and hemodynamic outcomes for the DurAVR® Transcatheter Heart Valve (THV) in 100 patients with severe aortic stenosis and small aortic annuli (annulus area 404 ± 37 mm2), the anatomy in which transcatheter valves most often leave patients with elevated gradients and prosthesis-patient mismatch* (PPM).
At 1 year,
These results were achieved in a symptomatic and clinically complex population. At baseline,
The late-breaking abstract, titled “One-Year Clinical and Hemodynamic Outcomes of a Novel Biomimetic Balloon-Expandable THV in Small Aortic Annuli,” was presented by Rishi Puri, MD, PhD, of Cleveland Clinic, during the TAVI Hotline – Part 1 session at PCR London Valves on Sunday, November 22, 2026.
1 Year Results Highlights
- Heart failure hospitalization:
1% at 1 year compares favorably to mid-to-high single-digit rates reported in contemporary clinical trials with currently marketed products.1,2 - Hemodynamics: Mean pressure gradient fell from 48.1 ± 17.0 mmHg at baseline to 8.9 ± 4.3 mmHg at 1 year, and mean EOA increased from 0.8 ± 0.2 cm2 to 2.2 ± 0.9 cm2. These results were similar to those reported at 30 days in 2025.
- Hemodynamic Valve Deterioration: No moderate or severe hemodynamic valve deterioration was observed at 1 year.
- Valve performance: No moderate or severe PVL was observed and no valve-related deaths were reported through 1 year.
- Symptoms: Patients in NYHA class I/II increased from
39% at baseline to96% at 1 year, and81% of patients experienced symptom improvement. - Clinical events at 1 year: All-cause mortality
6% (2 CV mortalities; 2 non-cardiac infections; 1 cancer; 1 car accident), stroke3% and new permanent pacemaker implantation9% . - Cardiac remodeling: In a cardiac magnetic resonance (CMR) substudy (n = 64), left ventricular (LV) mass, a marker of modifying the underlying disease, regressed by
24% at 1 year. LV mass in the patients evaluated was similar to that reported in matched controls without aortic valve disease3. These findings are consistent with sustained unloading of the left ventricle.
“Small aortic annuli are where we most often see elevated gradients and mismatch after TAVR, and these patients are disproportionately women. In this symptomatic cohort, DurAVR delivered single-digit gradients, no moderate or greater paravalvular leak and
“Small annuli are the hardest test in TAVR, and these patients were symptomatic, with
“Reducing heart failure hospitalization is among the most consequential events after aortic valve replacement, due to its proven correlation with CV mortality. In a pooled analysis of more than 3,400 patients treated with TAVR or surgical aortic valve replacement in the PARTNER trials, the 1-year heart failure hospitalization rate was
The DurAVR THV is being studied in the pivotal PARADIGM Trial (ClinicalTrials.gov ID NCT07194265), a randomized, head-to-head comparison against commercially available TAVR valves that is actively enrolling patients across the United States and Europe.
1Huded CP, et al. Circ Cardiovasc Interv. 2022;15(12):e012195.
2Herrmann HC, et al. Self-Expanding or Balloon-Expandable TAVR in Patients with a Small Aortic Annulus. N Engl J Med. 2024;390:1959-1971. Component rates (Kaplan-Meier) from SMART results posted at ClinicalTrials.gov, NCT04722250.
3Garg P, et al. European Heart Journal, Valvular & Structural Disease; 2026.
*Prosthesis-patient mismatch (PPM) occurs when an implanted valve’s effective opening is too small for the patient’s body size, resulting in higher-than-expected gradients. PPM is common after transcatheter aortic valve replacement (TAVR) in patients with small aortic annuli and has been associated with reduced long-term survival after surgical aortic valve replacement (SAVR).
About the PARADIGM Trial
The PARADIGM Trial is a prospective randomized controlled trial which will evaluate the safety and effectiveness of the DurAVR Transcatheter Heart Valve compared to commercially available transcatheter aortic valve replacements (TAVRs).
This head-to-head study will enroll approximately 1,000 patients in the ‘All Comers Randomized Cohort' with 1:1 randomization of patients who will receive either the DurAVR THV or TAVR using commercially available and approved THVs. The PARADIGM Trial will assess non-inferiority on a primary composite endpoint of all-cause mortality, all stroke and cardiovascular hospitalization at one year post procedure.
For further information, please refer to ClinicalTrials.gov NCT07194265.
About Anteris
Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) is a global healthcare company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Founded in Australia, with a significant presence in Minneapolis, USA, Anteris is a science-driven company with an experienced team of multidisciplinary professionals delivering restorative solutions to structural heart disease patients.
Anteris’ lead product, the DurAVR THV, was designed in collaboration with the world’s leading interventional cardiologists and cardiac surgeons to treat aortic stenosis – a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. DurAVR THV is made using a single piece of molded ADAPT® tissue, Anteris’ patented anti-calcification tissue technology. ADAPT tissue, which is FDA-cleared, has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide. The DurAVR THV System is comprised of the DurAVR valve, the ADAPT tissue, and the balloon-expandable ComASUR® Delivery System.
DurAVR THV is intended for INVESTIGATIONAL USE ONLY. Not available for commercial use or sale worldwide. CAUTION—Investigational device. Limited by Federal (or United States) law to investigational use.
Forward-Looking Statements
This announcement contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. Forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “budget,” “target,” “aim,” “strategy,” “plan,” “guidance,” “outlook,” “may,” “should,” “could,” “will,” “would,” “will be,” “will continue,” “will likely result” and similar expressions, although not all forward-looking statements contain these identifying words. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions, including those described under “Risk Factors” in Anteris’ Annual Report on Form 10-K for the fiscal period ended December 31, 2025 and subsequent Quarterly Reports on Form 10-Q, that were filed with the Securities and Exchange Commission and ASX. Early or pooled clinical results, including those described in this announcement, may not be predictive of future results, including results in the PARADIGM pivotal trial. Readers are cautioned not to put undue reliance on forward-looking statements, and except as required by law, Anteris does not assume any obligation to update any of these forward-looking statements to conform these statements to actual results or revised expectations.
For more information:
| Global Investor Relations | Investor Relations (US) |
| investors@anteristech.com | mchatterjee@bplifescience.com |
| Debbie Ormsby | Malini Chatterjee, Ph.D. |
| Anteris Technologies Global Corp. | Blueprint Life Science Group |
| +61 1300 550 310 | +61 7 3152 3200 | +1 917 330 4269 |
| Website | www.anteristech.com |
| X | @AnterisTech |
| https://www.linkedin.com/company/anteristech |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.